Novo Nordisk warns of near‑term sales hit from U.S. pricing, rising GLP‑1 competition

Headline: Novo Nordisk warns of near‑term sales hit from U.S. pricing and growing GLP‑1 competition

Novo Nordisk signals pricing‑driven slowdown, touts pill launch and access push

Novo Nordisk is pre‑releasing a 2026 outlook that flags material near‑term weakness in sales and operating profit as U.S. pricing pressures and the end of exclusivity for its semaglutide products reduce revenue headroom. Management cites significantly lower U.S. prices for Wegovy and escalating competition from cheaper semaglutide knock‑offs produced by compounding pharmacies and rivals such as Eli Lilly as the primary drivers of the anticipated 2026 decline. CEO Mike Doustdar frames the move as a short‑term trade‑off to improve affordability for millions of patients, saying the business “goes down before it comes back up” while positioning for longer‑term growth in GLP‑1 therapies.

The company highlights a strong early uptake for the Wegovy pill in the U.S., which reaches roughly 170,000 patients in the first month and meets efficacy expectations cited by management, alongside recent U.K. approval for a higher‑dose injection. Novo Nordisk stresses, however, that the positive launch momentum does not fully offset the price impact on its established injectable business in the near term. The firm does not yet detail the full magnitude of U.S. pricing effects in its pre‑release, prompting analysts to debate whether the conservative guidance is a deliberate “kitchen sink” that the company intends to beat, or a realistic calibration of sustained margin pressure.

The announcement underscores a wider industry shift where patent expirations, payer scrutiny and rapid competitive entry reshape commercial strategies for GLP‑1 drugs. Novo Nordisk frames its approach as balancing immediate affordability and access against longer‑term demand for obesity and diabetes therapies, while signalling that the path to recovery could be either swift or protracted depending on pricing dynamics, regulatory responses and the pace of new product uptake. The company prepares to manage expectations ahead of full‑year results as it navigates these structural market changes.

Cycling sponsorship underlines public‑health mission

Team Novo Nordisk is confirmed as a wildcard for the Milan‑Sanremo monument, using the high‑profile race to showcase that people with diabetes can compete at elite levels. The appearance reinforces Novo Nordisk’s dual commercial and public‑health messaging: promoting product access while educating on diabetes management, nutrition and equipment for athletes with chronic conditions.

Sector backdrop keeps pricing and patent expiries in focus

The development arrives as analysts and industry watchers concentrate on drug pricing, guidance and patent cliffs across the pharmaceutical sector. Ongoing regulatory decisions, the roll‑out of competing GLP‑1 formats and public‑policy debates on affordability are determining near‑term strategy for major drugmakers.